Q3 2024 |
29 |
$2.83B |
+$314M |
-$432M |
-$118M |
NICE, BIDU, PYPL, ELAN, NTR
|
13F-HR |
11/13/2024, 01:06 PM |
Q2 2024 |
34 |
$2.69B |
+$136M |
-$485M |
-$350M |
IPG, NTR, ELAN, BIDU, PYPL
|
13F-HR |
8/9/2024, 01:31 PM |
Q1 2024 |
37 |
$3.31B |
+$314M |
-$204M |
+$110M |
BIDU, IPG, ELAN, NTR, PYPL
|
13F-HR |
5/15/2024, 12:36 PM |
Q4 2023 |
37 |
$3.05B |
+$214M |
-$153M |
+$61.1M |
ELAN, IPG, NICE, PYPL, ZBRA
|
13F-HR |
2/13/2024, 10:40 AM |
Q3 2023 |
39 |
$2.75B |
+$207M |
-$102M |
+$105M |
NTR, BIDU, IPG, SRCL, PYPL
|
13F-HR |
11/13/2023, 10:53 AM |
Q2 2023 |
38 |
$2.86B |
+$382M |
-$208M |
+$174M |
IPG, BIDU, ZBRA, NTR, PYPL
|
13F-HR |
8/10/2023, 09:18 AM |
Q1 2023 |
38 |
$2.72B |
+$349M |
-$221M |
+$128M |
IPG, ZBRA, PYPL, BIDU, SRCL
|
13F-HR |
5/9/2023, 11:19 AM |
Q4 2022 |
38 |
$2.34B |
+$200M |
-$453M |
-$253M |
IPG, BIDU, SRCL, PYPL, ZBRA
|
13F-HR |
2/14/2023, 12:28 PM |
Q3 2022 |
2 |
$11.8M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:33 PM |
Q3 2022 |
40 |
$2.42B |
+$195M |
-$395M |
-$199M |
IPG, BIDU, BAH, SRCL, PYPL
|
13F-HR |
11/9/2022, 12:02 PM |
Q2 2022 |
2 |
$12M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:32 PM |
Q2 2022 |
38 |
$2.79B |
+$428M |
-$934M |
-$506M |
BAH, BIDU, IPG, SRCL, PYPL
|
13F-HR |
8/11/2022, 11:00 AM |
Q1 2022 |
2 |
$12.5M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:32 PM |
Q1 2022 |
36 |
$3.55B |
+$228M |
-$450M |
-$223M |
BAH, IPG, BIDU, GSK, NTR
|
13F-HR |
5/6/2022, 07:37 AM |
Q4 2021 |
2 |
$16.4M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:31 PM |
Q4 2021 |
35 |
$3.75B |
+$629M |
-$410M |
+$219M |
BAH, GSK, IPG, BIDU, NTR
|
13F-HR |
2/15/2022, 10:30 AM |
Q3 2021 |
2 |
$15.1M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:30 PM |
Q3 2021 |
35 |
$3.44B |
+$517M |
-$251M |
+$266M |
BAH, IPG, GSK, BIDU, IBN
|
13F-HR |
11/5/2021, 10:22 AM |
Q2 2021 |
2 |
$14.6M |
$0 |
$0 |
|
|
New Holdings |
2/14/2023, 12:29 PM |
Q2 2021 |
36 |
$3.23B |
+$324M |
-$285M |
+$38.4M |
BAH, IPG, GSK, BIDU, ORCL
|
13F-HR |
8/12/2021, 04:59 PM |
Q1 2021 |
31 |
$3.02B |
+$471M |
-$916M |
-$445M |
BAH, IPG, ORCL, GSK, IBN
|
13F-HR |
5/6/2021, 11:07 AM |
Q4 2020 |
33 |
$3.21B |
+$294M |
-$346M |
-$51.6M |
IPG, NTR, IBN, BIDU, GSK
|
13F-HR |
2/8/2021, 04:09 PM |
Q3 2020 |
31 |
$2.63B |
+$175M |
-$171M |
+$3.9M |
NTR, IPG, BIDU, GSK, BAH
|
13F-HR |
11/9/2020, 11:26 AM |
Q2 2020 |
31 |
$2.48B |
+$98.8M |
-$416M |
-$318M |
IPG, NTR, BWA, GSK, IBN
|
13F-HR |
8/11/2020, 12:09 PM |
Q1 2020 |
32 |
$2.49B |
+$465M |
-$405M |
+$59.8M |
NTR, IPG, GSK, ORCL, BWA
|
13F-HR |
5/8/2020, 11:16 AM |
Q4 2019 |
32 |
$3.18B |
+$242M |
-$137M |
+$105M |
GSK, IPG, IBN, NTR, ORCL
|
13F-HR |
2/11/2020, 04:37 PM |
Q3 2019 |
32 |
$2.86B |
+$306M |
-$426M |
-$120M |
GSK, ORCL, IPG, IBN, NLSN
|
13F-HR |
11/12/2019, 10:58 AM |
Q2 2019 |
31 |
$3.03B |
+$369M |
-$396M |
-$26.8M |
GSK, BWA, ORCL, IPG, BSMX
|
13F-HR |
8/13/2019, 02:09 PM |
Q1 2019 |
27 |
$2.93B |
+$192M |
-$318M |
-$126M |
GSK, BAH, BSMX, IBN, NLSN
|
13F-HR |
5/13/2019, 12:26 PM |
Q4 2018 |
26 |
$2.76B |
+$121M |
-$281M |
-$160M |
GSK, BSMX, IBN, NLSN, ORCL
|
13F-HR |
2/12/2019, 10:41 AM |
Q3 2018 |
26 |
$3.29B |
+$106M |
-$272M |
-$166M |
BSMX, ORCL, IBN, BAH, NLSN
|
13F-HR |
11/9/2018, 11:02 AM |
Q2 2018 |
28 |
$3.28B |
+$336M |
-$158M |
+$178M |
IBN, ORCL, BAH, NLSN, BSMX
|
13F-HR |
8/13/2018, 01:46 PM |
Q1 2018 |
28 |
$3.06B |
+$962M |
-$373M |
+$589M |
IBN, BSMX, ORCL, NLSN, BAH
|
13F-HR |
5/11/2018, 10:26 AM |
Q4 2017 |
27 |
$2.66B |
+$545M |
-$125M |
+$419M |
IBN, ORCL, NLSN, BSMX, BAH
|
13F-HR |
2/9/2018, 10:42 AM |
Q3 2017 |
26 |
$2.27B |
+$384M |
-$88.7M |
+$295M |
IBN, NLSN, ORCL, BSMX, INOV
|
13F-HR |
11/13/2017, 10:25 AM |
Q2 2017 |
23 |
$1.89B |
+$386M |
-$108M |
+$279M |
IBN, ORCL, BSMX, NLSN, FCN
|
13F-HR |
8/14/2017, 02:23 PM |
Q1 2017 |
19 |
$1.59B |
+$251M |
-$124M |
+$127M |
IBN, BSMX, ORCL, FCN, NLSN
|
13F-HR |
5/15/2017, 11:15 AM |
Q4 2016 |
18 |
$1.3B |
+$183M |
-$75.3M |
+$108M |
IBN, FCN, ORCL, BSMX, GRFS
|
13F-HR |
2/14/2017, 10:24 AM |
Q3 2016 |
18 |
$1.23B |
+$93.7M |
-$60.4M |
+$33.3M |
IBN, FCN, ORCL, BSMX, CCL
|
13F-HR |
11/14/2016, 11:27 AM |
Q2 2016 |
18 |
$1.17B |
$0 |
$0 |
|
IBN, ORCL, BSMX, FCN, INOV
|
New Holdings |
8/16/2016, 04:35 PM |
Q2 2016 |
18 |
$1.17B |
+$153M |
-$106M |
+$47.1M |
IBN, ORCL, BSMX, FCN, INOV
|
13F-HR |
8/12/2016, 01:03 PM |
Q1 2016 |
19 |
$1.13B |
+$191M |
-$55.7M |
+$135M |
IBN, ORCL, FCN, BSMX, HAE
|
13F-HR |
5/13/2016, 10:14 AM |
Q4 2015 |
18 |
$985M |
+$261M |
-$53.5M |
+$207M |
ORCL, IBN, FCN, BSMX, TV
|
13F-HR |
2/16/2016, 11:30 AM |
Q3 2015 |
18 |
$760M |
+$161M |
-$126M |
+$35.8M |
FCN, ORCL, CCL, HAE, IBN
|
13F-HR |
11/13/2015, 11:06 AM |
Q2 2015 |
17 |
$815M |
+$77.5M |
-$100M |
-$22.8M |
FCN, CCL, ORCL, HAE, IBN
|
13F-HR |
8/14/2015, 12:49 PM |
Q1 2015 |
18 |
$824M |
+$61.9M |
-$69.9M |
-$8.09M |
FCN, CCL, ORCL, TV, HAE
|
13F-HR |
5/11/2015, 12:48 PM |
Q4 2014 |
17 |
$809M |
+$79.4M |
-$130M |
-$50.2M |
FCN, ORCL, CCL, EBAY, TV
|
13F-HR |
2/4/2015, 01:40 PM |
Q3 2014 |
16 |
$870M |
+$24.4M |
-$65.7M |
-$41.3M |
TV, ORCL, CCL, EBAY, FCN
|
13F-HR |
11/14/2014, 10:17 AM |
Q2 2014 |
16 |
$952M |
+$135M |
-$81.8M |
+$53.3M |
TV, ORCL, FCN, CCL, EBAY
|
13F-HR |
8/14/2014, 10:23 AM |
Q1 2014 |
17 |
$915M |
+$188M |
-$99.7M |
+$88M |
TV, ORCL, CCL, FCN, MR
|
13F-HR |
5/14/2014, 04:05 PM |
Q4 2013 |
17 |
$850M |
$0 |
$0 |
|
WX, ORCL, CCL, TV, FCN
|
13F-HR |
2/13/2014, 10:44 AM |